patent war Natra, cell-free DNA testing companies, CareDxThe precision medicine company serving transplant patients, continued this week, with Natera now filing two new patent infringement lawsuits against CareDx.
Natera accuses CareDx Two patents for Natera’s DNA detection technology were violated, according to documents filed Friday in U.S. District Court in Delaware.
The Austin, Texas-based company claims that CareDx’s Allosure and AlloSeq products infringe Patent No. 10,655,180. According to court documents, the patent relates to Natera’s products for measuring DNA in samples using synthetic DNA fragments, including amplification products produced using synthetic tools such as primers.
“CareDx has made extensive use of Natera’s patented technology, including that described and claimed in the ‘180 patent,” according to complaint.
Natera also claimed that in a separate case AlloSure, AlloSeq, KidneyCare and HeartCare products from CareDx Infringes US Patent No. 11111544.
It’s the latest gunfire in an ongoing conflict between the two companies. March, A sort of Jury finds Natera owed $12 million $44.9 Damage to CareDx. The jury found that Natera deliberately misled the transplant community by comparing its Prospera kidney transplant technology to CareDx’s AlloSure test; CareDx did not escape verdict in the verdict that the jury found CareDx engaged in two false advertising accounts.
The conflict dates back several years, when San Francisco-based CareDx filed a lawsuit against Natera in 2019, alleging false advertising of its products and comparing them to CareDx’s. At the heart of both Prospera and AlloSure are blood tests that can assess the risk of kidney transplant rejection.
In a press release Tuesday, CareDx said, “It is believed that all recycling patents against CareDx are invalid and not violated.”
Attorneys for Natera did not immediately respond to a request for comment.
the case is 1:22-cv-00641-CFC and 1:22-cv-00642-CFC in the District Court of Delaware.
